Vivani Medical Developing GLP-1 Implant for Long-Term Weight Loss Maintenance
Biotech company Vivani Medical is developing an experimental implant containing semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. The goal is to help patients maintain weight loss by reducing treatment frequency from daily injections to potentially once a year. This partnership with Novo Nordisk aims to address adherence challenges associated with current GLP-1 therapies.
Tickers: $NVO
Topics: GLP-1 drugs obesity treatment semaglutide implant Vivani Medical